Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
Rhea-AI Summary
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has regained compliance with Nasdaq's listing requirements. The company has met both the minimum bid price requirement of $1.00 per share and the minimum shareholders' equity requirement of $2.5 million.
The company is preparing for Phase 2/3 clinical trials of its SIL204 therapy, scheduled for the first half of 2026. Recent preclinical data showed promising results with up to 97% inhibition rates across multiple KRAS-driven cancer types. Silexion has also established a strategic CRO collaboration to advance its clinical development strategy.
Positive
- Regained compliance with Nasdaq listing requirements, maintaining market visibility and investor access
- Preclinical data showed strong 97% inhibition rates across multiple cancer types
- Strategic CRO collaboration established for clinical development
- Phase 2/3 clinical trials for SIL204 planned for H1 2026
Negative
- Previous non-compliance with listing requirements indicates recent financial challenges
- Phase 2/3 trials not starting until H1 2026, suggesting extended timeline to market
News Market Reaction
On the day this news was published, SLXN declined 2.20%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital Market
GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), concerning the minimum bid price and shareholders' equity requirements.
The letter, dated September 23, 2025, confirmed that the Company has successfully met the minimum bid price requirement of
"We are pleased to have regained full compliance with Nasdaq's listing requirements," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "This milestone reinforces our strong financial foundation as we advance toward our planned Phase 2/3 clinical trials for SIL204 in the first half of 2026. With our recent preclinical data demonstrating up to
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, clinical development plans, timeline for Phase 2/3 trials, and expectations regarding SIL204's therapeutic potential, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
FAQ
Why did Silexion Therapeutics (SLXN) regain Nasdaq compliance in September 2025?
What are the key clinical developments for Silexion Therapeutics (SLXN)?
What type of therapy is Silexion Therapeutics (SLXN) developing?
When will Silexion Therapeutics (SLXN) begin its Phase 2/3 trials for SIL204?
